Martinelli's recalls 170,000 juice bottles over toxic fungi risk
The recall covers round glass 10-ounce bottles with white metal screw-top lids that were distributed in 28 states, from Alabama to Wisconsin, according to the FDA recall notice. S. Martinelli & Co., the Watsonville, California, beverage company that makes the drink, didn't immediately respond to a request for comment.
The recall is listed as Class II, which under FDA guidelines signals that a product may "cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."
Patulin is a mycotoxin that's produced by a number of fungal species and is usually associated with foods infected by those fungi, including apples, according to the peer-reviewed journal Toxicon. Its side effects can include nausea, vomiting and diarrhea, the journal Frontiers in Science notes.
Below are the states where the Martinelli's juice bottles were distributed:
AlabamaArkansasArizonaCaliforniaConnecticutDelawareFloridaGeorgiaIowa IllinoisIndianaKansasKentuckyLouisianaMichiganMissouriMississppiNorth CarolinaNew HampshireNew JerseyNew YorkOhioPennsylvaniaSouth CarolinaTexasUtahVirginiaWisconsin
The bottles have a "best by" date of December 5, 2026, and a UPC code of: 0 41244 04102 2.
The life of teen idol Bobby Darin
Bill Belichick on a life in football
Pope Francis laid to rest
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Newsweek
an hour ago
- Newsweek
Toothpaste Recalled Nationwide as FDA Issues Risk Warning
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A nationwide recall of more than 40,000 units of toothpaste has received the lowest risk level by the Food and Drug Administration. A recall for Sensodyne Pronamel Active Shield Toothpaste for Sensitive Teeth began on August 5 over concerns that "Fresh Mint" tubes were mislabeled "Cool Mint/Whitening." The outer carton was labeled accurately. FDA inspectors classified the recall as a Class III, the lowest of three risk levels, on Tuesday, indicating the mix-up was "not likely to cause adverse health consequences." Newsweek contacted Haleon, which makes Sensodyne, via email on Tuesday. Why It Matters The FDA assigned this recall a Class III designation, which applies to situations where the use of or exposure to the recalled product is not likely to cause adverse health consequences. While the FDA determined the risk to be minimal, the corrective move underscores the regulatory attention to food contact safety and manufacturing consistency. A stock photo shows someone ready to clean their teeth. A stock photo shows someone ready to clean their teeth. Getty Images What To Know The FDA recall entry listed the product as Sensodyne Pronamel (potassium nitrate 5 percent, sodium fluoride 0.25 percent) Active Shield Toothpaste for Sensitive Teeth, Fresh Mint, Net WT 3.4 ounces (96.4 grams). The product came in cases containing six tubes, and the recall affected 46,692 tubes, the FDA alert said. It added that the products were recalled by New York-based Haleon U.S. Holdings after having been distributed nationwide by GSK Consumer Healthcare. The FDA's new classification record listed the recall reason as "labeling." "Label Mix-up: The outer carton is labeled Fresh Mint. The tube is labeled Cool Mint/Whitening. The toothpaste inside the tube is Fresh Mint as indicated on the outer carton," the alert said. The recall entry included lot and expiration information. The case lot number is 5058RB, and the carton and tube lot number is NJ2A. Both had an expiry date of August 31, 2027. FDA inspectors carry out a hazard assessment before issuing one of three risk levels. The three classifications are these: Class I —a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. —a situation in which there is a reasonable probability that the use of, or exposure to, a violative product will cause serious adverse health consequences or death. Class II —a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. —a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. Class III—a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences. What People Are Saying The Food and Drug Administration said on its website: "Product problems should be reported to the FDA when there is a concern about the quality, authenticity, performance, or safety of any medication or device. Problems with product quality may occur during manufacturing, shipping, or storage. They include … labeling concerns." What Happens Next The FDA lists the recall as ongoing. The alert did not provide consumer return or disposal instructions.
Epoch Times
an hour ago
- Epoch Times
FDA Warns Public Over Potentially Radioactive Walmart Shrimp
The Food and Drug Administration (FDA) on Tuesday told the U.S. public not to eat, sell, or serve certain imported Walmart frozen shrimp produced by an Indonesian company because it may have been exposed to a radioactive material. Health officials said in a statement that it is investigating reports of Cesium-137 contamination in shipping containers as well as shrimp products that were processed by Indonesia-based PT. Bahari Makmur Sejati, also known as BMS Food.
